These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 17699748)

  • 1. Targeting oncogenic Ras.
    Diaz-Flores E; Shannon K
    Genes Dev; 2007 Aug; 21(16):1989-92. PubMed ID: 17699748
    [No Abstract]   [Full Text] [Related]  

  • 2. [Ha-ras, N-ras et Ki-ras].
    Soussi T
    Bull Cancer; 2001 Feb; 88(2):131-3. PubMed ID: 11291662
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Blocking oncogenic Ras signaling for cancer therapy.
    Canevari S; Biocca S; Figini M
    J Natl Cancer Inst; 2002 Jul; 94(13):1031-2; author reply 1032. PubMed ID: 12096090
    [No Abstract]   [Full Text] [Related]  

  • 4. The impact of the regulatory design on the response of epidermal growth factor receptor-mediated signal transduction towards oncogenic mutations.
    Wolf J; Dronov S; Tobin F; Goryanin I
    FEBS J; 2007 Nov; 274(21):5505-17. PubMed ID: 17916191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation.
    Konishi H; Karakas B; Abukhdeir AM; Lauring J; Gustin JP; Garay JP; Konishi Y; Gallmeier E; Bachman KE; Park BH
    Cancer Res; 2007 Sep; 67(18):8460-7. PubMed ID: 17875684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovative treatment programs against cancer. I. Ras oncoprotein as a molecular target.
    Waddick KG; Uckun FM
    Biochem Pharmacol; 1998 Dec; 56(11):1411-26. PubMed ID: 9827573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical target promiscuity: lessons from ras molecular trials.
    Rengan R; Cengel KA; Hahn SM
    Cancer Metastasis Rev; 2008 Sep; 27(3):403-14. PubMed ID: 18461427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular signaling from Ras to genes: an MCDB/ISU symposium held at Iowa State University, Ames, September 22-25, 1994.Introduction.
    Nilsen-Hamilton M; Buss J; Hamilton RT
    Mol Reprod Dev; 1995 Dec; 42(4):457-8. PubMed ID: 8607976
    [No Abstract]   [Full Text] [Related]  

  • 9. Synthetic lethal genetic screens in Ras mutant cancers.
    Yu B; Luo J
    Enzymes; 2013; 34 Pt. B():201-19. PubMed ID: 25034106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling.
    Lee SG; Su ZZ; Emdad L; Sarkar D; Franke TF; Fisher PB
    Oncogene; 2008 Feb; 27(8):1114-21. PubMed ID: 17704808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NADPH oxidase 1 plays a critical mediating role in oncogenic Ras-induced vascular endothelial growth factor expression.
    Komatsu D; Kato M; Nakayama J; Miyagawa S; Kamata T
    Oncogene; 2008 Aug; 27(34):4724-32. PubMed ID: 18454179
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumor activity of ESX1 on cancer cells harboring oncogenic K-ras mutation.
    Nakajima J; Ishikawa S; Hamada J; Yanagihara M; Koike T; Hatakeyama M
    Biochem Biophys Res Commun; 2008 May; 370(1):189-94. PubMed ID: 18361917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further evidence for a somatic KRAS mutation in a pilocytic astrocytoma.
    Janzarik WG; Kratz CP; Loges NT; Olbrich H; Klein C; Schäfer T; Scheurlen W; Roggendorf W; Weiller C; Niemeyer C; Korinthenberg R; Pfister S; Omran H
    Neuropediatrics; 2007 Apr; 38(2):61-3. PubMed ID: 17712732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Ras inhibitor farnesylthiosalicylic acid (Salirasib) disrupts the spatiotemporal localization of active Ras: a potential treatment for cancer.
    Rotblat B; Ehrlich M; Haklai R; Kloog Y
    Methods Enzymol; 2008; 439():467-89. PubMed ID: 18374183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Survival of skin allografts is prolonged in mice with a dominant-negative H-Ras.
    Funeshima-Fuji N; Fujino M; Kimura H; Takahara S; Nakayama T; Ezaki T; Li XK
    Transpl Immunol; 2008 Feb; 18(4):302-6. PubMed ID: 18158115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Proteomic approach for protein-profiling the oncogenic ras induced transformation (H-, K-, and N-Ras) in NIH/3T3 mouse embryonic fibroblasts.
    Kim S; Lee YZ; Kim YS; Bahk YY
    Proteomics; 2008 Aug; 8(15):3082-93. PubMed ID: 18601226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS and Hedgehog--partners in crime.
    Lauth M
    Front Biosci (Landmark Ed); 2011 Jun; 16(6):2259-70. PubMed ID: 21622175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutationally activated K-ras 4A and 4B both mediate lung carcinogenesis.
    Patek CE; Arends MJ; Wallace WA; Luo F; Hagan S; Brownstein DG; Rose L; Devenney PS; Walker M; Plowman SJ; Berry RL; Kolch W; Sansom OJ; Harrison DJ; Hooper ML
    Exp Cell Res; 2008 Mar; 314(5):1105-14. PubMed ID: 18062963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An enhanced association of RACK1 with Abl in cells transfected with oncogenic ras.
    Huang CC; Liu CH; Chuang NN
    Int J Biochem Cell Biol; 2008; 40(3):423-31. PubMed ID: 17881279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
    Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
    Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.